Press release
Epilepsy Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis | Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai
Epilepsy Pipeline Analysis
Epilepsy Pipeline constitutes 75+ key companies continuously working towards developing 90+ Epilepsy treatment therapies, analyzes DelveInsight.
Epilepsy Overview:
Epilepsy is a common and serious neurological disorder affecting over 50 million people worldwide. It is defined by a long-term tendency to experience epileptic seizures, often accompanied by cognitive, psychological, and social difficulties. The condition has a bimodal distribution, with highest incidence in infants and older adults.
Seizures in epilepsy result from abnormal and excessive electrical activity in the brain. These can cause a range of symptoms-both visible and sensory-such as loss of awareness, muscle stiffening or jerking, unusual sensations like deja vu, or strange smells. Seizures are unpredictable and vary in type and severity.
Epilepsy is a non-communicable, chronic brain disorder where normal neural function becomes disrupted, leading to recurring seizures. Under normal conditions, neurons transmit electrical impulses in a controlled way using neurotransmitters. In epilepsy, this system becomes hyperactive, often due to changes in ion balance, receptor function, energy metabolism, or neurotransmitter regulation, turning regular neural circuits into hyperexcitable networks.
Request for a detailed insights report on Epilepsy pipeline insights @ https://www.delveinsight.com/report-store/epilepsy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
"Epilepsy Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Epilepsy Therapeutics Market.
Key Takeaways from the Epilepsy Pipeline Report
*
DelveInsight's epilepsy pipeline report highlights a dynamic landscape, with over 75 companies actively developing more than 90 pipeline therapies targeting epilepsy.
*
In January 2025, Alembic received FDA approval for a generic version of AbbVie's Depakote Sprinkle-divalproex sodium delayed-release capsules (125 mg)-an anti-epileptic used to treat various seizure types, including complex partial seizures and absence seizures, and as adjunct therapy.
*
In December 2025, Aquestive Therapeutics (NASDAQ: AQST) was granted seven years of orphan drug exclusivity by the FDA for Libervant Registered (diazepam) Buccal Film, a novel treatment for acute seizure clusters in epilepsy patients aged 2 to 5 years.
*
Leading companies such as UCB, SK Life Science, Stoke Therapeutics, Xenon Pharmaceuticals, Epygenix, and many others are advancing innovative therapies to enhance epilepsy management. Notable pipeline candidates include EPX-100, BMB-101, STK-001, NRTX-1001, IAMA-6, among others, which are in various stages of clinical development.
Epilepsy Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the Epilepsy Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Epilepsy treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Epilepsy market.
Download our free sample page report on Epilepsy pipeline insights [https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Epilepsy Emerging Drugs
*
EPX-100: Harmony Biosciences
*
BMB-101: Bright Minds Biosciences
*
STK-001: Stoke Therapeutics
*
NRTX-1001: Neurona Therapeutics
*
IAMA-6: IAMA Therapeutics
Epilepsy Companies
Approximately 75 key companies are actively developing therapies for epilepsy. Among them, Harmony Biosciences has an epilepsy drug candidate in the most advanced stage of development, namely Phase III.
DelveInsight's report covers around 90+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Epilepsy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Epilepsy Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Epilepsy Therapies and Key Companies: Epilepsy Clinical Trials and advancements [https://www.delveinsight.com/report-store/epilepsy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Epilepsy Pipeline Therapeutic Assessment
- Epilepsy Assessment by Product Type
- Epilepsy By Stage
- Epilepsy Assessment by Route of Administration
- Epilepsy Assessment by Molecule Type
Download Epilepsy Sample report to know in detail about the Epilepsy treatment market @ Epilepsy Therapeutic Assessment [https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Epilepsy Current Treatment Patterns
4. Epilepsy - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Epilepsy Late-Stage Products (Phase-III)
7. Epilepsy Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Epilepsy Discontinued Products
13. Epilepsy Product Profiles
14. Epilepsy Key Companies
15. Epilepsy Key Products
16. Dormant and Discontinued Products
17. Epilepsy Unmet Needs
18. Epilepsy Future Perspectives
19. Epilepsy Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Epilepsy Pipeline Reports Offerings [https://www.delveinsight.com/report-store/epilepsy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=epilepsy-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-and-pipeline-analysis-miltenyi-biomedicine-adicet-bio-velosbio-novartis-pharmaceuticals-sanofi-eisai]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Epilepsy Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis | Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai here
News-ID: 4106967 • Views: …
More Releases from ABNewswire
Denver's Best Appliance Repair Responds to Rising Demand for Emergency Appliance …
Denver's Best Appliance Repair expands emergency services across the Denver metro with same-day repairs, 7-day availability, 5-year parts warranty, and professional licensed technicians serving residential and commercial clients.
Household appliance failures don't follow a schedule. When a refrigerator stops cooling in the middle of summer or a washing machine floods a basement on a Sunday evening, families need immediate help. Denver's Best Appliance Repair has responded to this growing need by…
Oak Hill Clinic Reaches 30,000 Client Milestone with Results-Driven Deep Tissue …
Deep Relief in Oak Hill, Austin, has served 30,000 clients through specialized massage, chiropractic, and acupuncture care. The clinic accepts insurance and focuses on results-driven treatments for pain relief.
Deep Relief, an Oak Hill-based wellness clinic, has achieved a significant milestone by serving more than 30,000 clients seeking Relief from chronic pain, muscle tension, and mobility issues. The clinic's success stems from its commitment to advanced, results-focused bodywork that goes beyond…
Vertex Fleet Expands Nationwide Network to Combat Growing Trailer Drop Yard Shor …
Vertex Fleet announces major expansion of secure parking facilities nationwide, addressing the critical shortage of commercial vehicle storage with 15+ new locations featuring 24/7 security and technology-driven access.
The freight and logistics industry faces a mounting crisis as demand for secure parking spaces continues to outpace supply across the United States. Vertex Fleet [https://www.vertexfleet.com/], a leading provider of industrial outdoor storage solutions, has announced significant expansion plans to address this critical…
HVAC in Denver Sees Service Enhancement as Denver's Best Heating and AC Repair L …
Denver's Best Heating and AC Repair expands 24/7 emergency services across 23 metro cities, offering A+ rated heating, cooling, and commercial HVAC solutions with rapid response times and multi-brand expertise.
Denver's Best Heating and AC Repair [https://www.denversbestheatingandacrepair.com/]has expanded its service capabilities to meet growing demand for reliable heating and cooling solutions across the Denver Metro area. The A+ rated contractor now provides 24/7 emergency response services to 23 cities, addressing critical…
More Releases for Epilepsy
Adult mitochondrial epilepsy presentation
Mitochondrial epilepsy is a rare but severe neurological condition caused by genetic mutations that impair mitochondrial function, disrupting cellular energy production in the brain. Patients often present with seizures, developmental delays, and neurodegeneration. It is closely associated with broader mitochondrial diseases such as MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like Episodes) and Leigh syndrome.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72869
Due to its rarity and complexity, treatment options…
Portable Epilepsy Monitoring Market in 2025
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Portable Epilepsy Monitoring Market- (By Product Type (Device Type (Chest Sensor, Watch Sensor, Monitors, Cameras, Mattresses and Pillows, and Others) and Service), By End User (Hospitals, Ambulatory Surgery Centres & Clinics, Neurology Centres, and Home Care Settings)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
According to the latest research by InsightAce Analytic, the Global…
Top 10 Epilepsy Companies Analysis (2024)
Epilepsy also known as seizure disorder, is a chronic noncommunicable disease that affects brain. Epilepsy affects people of all races, ethnic backgrounds, genders, and ages.
Get More Details with Sample PDF Copy @ https://www.theinsightpartners.com/sample/TIPRE00016405/?utm_source=OpenPR&utm_medium=10129
Major Companies operating in the Epilepsy Market are:
• Idexx Laboratories Inc.
• PBD Biotech Ltd
• Thermo Fisher Scientific Inc.
• Innovative Diagnostics SAS
• Neogen Corp
• Enfer Labs
• bioMerieux SA
• Ring Biotechnology Co Ltd
• Bionote Inc.
• Shenzhen Bioeasy Biotechnology Co Ltd.
Contact Us:
If you have any queries about this report or if…
Epilepsy Market: Trends, Opportunities, and Challenges
Epilepsy is a neurological disorder characterized by recurrent seizures, which are caused by abnormal electrical activity in the brain. This condition affects millions of people globally, making it one of the most common neurological disorders. As the global burden of epilepsy increases, the demand for effective treatments and solutions continues to grow. The epilepsy market is evolving rapidly, with advancements in medication, diagnostics, and therapeutic technologies. This guest post aims…
Epilepsy Device Market: for Epilepsy Devices Poised to Exceed $1 Billion by 2031 …
The global epilepsy devices market isx experiencing a remarkable surge, poised to exceed a valuation of $1.1 billion by 2031, as revealed by the latest market analysis. According to the report released by Allied Market Research, the market was valued at $675.23 million in 2021 and is projected to grow at a CAGR of 5.1% from 2022 to 2031.
𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐅𝐨𝐫 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲: https://www.alliedmarketresearch.com/request-sample/A14821
Epilepsy devices play…
Epilepsy with Myoclonic - Atonic Seizures Therapeutics Market - Breaking the Sei …
Newark, New Castle, USA: The "Epilepsy with Myoclonic-Atonic Seizures Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Epilepsy with Myoclonic - Atonic Seizures Therapeutics Market: https://www.growthplusreports.com/report/epilepsy-with-myoclonic-atonic-seizures-therapeutics-market/8029
This…
